NEW YORK (GenomeWeb News) – Cell Biosciences has raised $10 million through a Series C private financing, the Palo Alto, Calif.-based firm said today.

The company has developed an "ultrasensitive" nanofluidic immunoassay system designed to analyze proteins in very small biological samples. It said researchers can use the system to discover details about phosphoprotein signaling in a wide variety of biological systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.